Totus Medicines
Making every disease treatable by making the total human genome druggable.
Making every disease treatable by making the total human genome druggable.
Totus Medicines is a biopharmaceutical startup founded in 2020 with a vision encapsulated in its slogan: "Making every disease treatable by making the total human genome druggable." The company's core focus lies in applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases. This ambitious goal has attracted significant investor interest, with the latest funding round amounting to a substantial $66.00M in a Series B investment at 15 December 2023. This round saw participation from a consortium of prominent backers including DCVC, Camford Capital, Northpond Ventures, and the Regents of The University of Minnesota. With its headquarters situated in the United States, Totus Medicines operates at the forefront of the biopharma and biotechnology industries, positioning itself as a key player in the advancement of druggable human genome therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $66.00M | 4 |
|
15 Dec 2023 |
| Series A | $40.00M | 3 |
|
09 Dec 2021 |
| Seed Round | Unknown | 1 |
|
04 Jul 2020 |
No recent news or press coverage available for Totus Medicines.
We care about your data, and we'd love to use cookies make your experience better.
